Literature DB >> 17338594

Psychostimulants in the treatment of depression : a review of the evidence.

Katy Orr1, David Taylor.   

Abstract

Psychostimulants have euphoric and alerting properties that suggest their usefulness in treating depressive disorders; however, problems with tolerance and dependence with some drugs militate against their widespread therapeutic use where more acceptable licensed alternatives are available. The introduction of modafinil, a stimulant not associated with tolerance and dependence, has re-awakened interest in psychostimulants as antidepressants. The available literature, while containing somewhat inconsistent data of rather poor quality, does suggest that psychostimulants have useful antidepressant properties and are usually well tolerated. They may be useful as adjuncts to standard antidepressants in refractory depression, but have particular utility in conditions where a prompt therapeutic effect is desired and where tolerance and dependence are less of a concern. Such conditions include the treatment of depression in terminal illness and in extreme old age.Psychostimulants, although now largely discarded as treatment options for depression, deserve careful consideration as potential therapeutic agents in specific patient subgroups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338594     DOI: 10.2165/00023210-200721030-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  78 in total

1.  Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine.

Authors:  S D Block
Journal:  Ann Intern Med       Date:  2000-02-01       Impact factor: 25.391

Review 2.  Diagnosis and treatment of depression in late life. Consensus statement update.

Authors:  B D Lebowitz; J L Pearson; L S Schneider; C F Reynolds; G S Alexopoulos; M L Bruce; Y Conwell; I R Katz; B S Meyers; M F Morrison; J Mossey; G Niederehe; P Parmelee
Journal:  JAMA       Date:  1997-10-08       Impact factor: 56.272

3.  ADHD drugs and cardiovascular risk.

Authors:  Steven E Nissen
Journal:  N Engl J Med       Date:  2006-03-20       Impact factor: 91.245

4.  Pemoline and methylphenidate in midly depressed outpatients.

Authors:  K Rickels; P E Gordon; D H Gansman; C C Weise; J A Pereira-Ogan; P T Hesbacher
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

5.  Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression.

Authors:  Mady Hornig-Rohan; Jay D Amsterdam
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-04       Impact factor: 5.067

6.  Psychostimulants for secondary depression in medical illness.

Authors:  P Masand; P Pickett; G B Murray
Journal:  Psychosomatics       Date:  1991       Impact factor: 2.386

7.  Psychostimulants in post-stroke depression.

Authors:  P Masand; G B Murray; P Pickett
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1991       Impact factor: 2.198

8.  Methylphenidate in terminal depression.

Authors:  A D Macleod
Journal:  J Pain Symptom Manage       Date:  1998-09       Impact factor: 3.612

Review 9.  Can long-term treatment with antidepressant drugs worsen the course of depression?

Authors:  Giovanni A Fava
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

10.  Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

Authors:  Charles DeBattista; Karl Doghramji; Matthew A Menza; Murray H Rosenthal; Ronald R Fieve
Journal:  J Clin Psychiatry       Date:  2003-09       Impact factor: 4.384

View more
  7 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  Prescription use disorders in older adults.

Authors:  Raj K Kalapatapu; Maria A Sullivan
Journal:  Am J Addict       Date:  2010-09-21

3.  Improvement in depression scores after 1 hour of light therapy treatment in patients with seasonal affective disorder.

Authors:  Gloria M Reeves; Gagan Virk Nijjar; Patricia Langenberg; Mary A Johnson; Baharak Khabazghazvini; Aamar Sleemi; Dipika Vaswani; Manana Lapidus; Partam Manalai; Muhammad Tariq; Monika Acharya; Johanna Cabassa; Soren Snitker; Teodor T Postolache
Journal:  J Nerv Ment Dis       Date:  2012-01       Impact factor: 2.254

Review 4.  Psychostimulants and cognition: a continuum of behavioral and cognitive activation.

Authors:  Suzanne Wood; Jennifer R Sage; Tristan Shuman; Stephan G Anagnostaras
Journal:  Pharmacol Rev       Date:  2013-12-16       Impact factor: 25.468

5.  Methylphenidate modulates activity within cognitive neural networks of patients with post-stroke major depression: A placebo-controlled fMRI study.

Authors:  Rajamannar Ramasubbu; Bradley G Goodyear
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

6.  Adult ADHD: Questioning Diagnosis and Treatment in a Patient with Multiple Psychiatric Comorbidities.

Authors:  Robert Karoly Chu; Tea Rosic; Zainab Samaan
Journal:  Case Rep Psychiatry       Date:  2017-06-11

7.  Effectiveness of methylphenidate as augmentation therapy after failure of adjunctive neuromodulation for patients with treatment-refractory bipolar depression: a case report.

Authors:  Marc Adida; Jean-Michel Azorin
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-02       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.